Engineering multivalent antibodies to target heregulin-induced HER3 signaling in breast cancer cells.

MAbs · 2014 · PMC3984324 · PMID 24492289

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Although BT-474 cells showed a trend toward heregulin-stimulated proliferation, differences between vehicle- and heregulin-treated cells were not always significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.